NCT04889066 2024-12-20
Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain Metastases
University of Texas Southwestern Medical Center
Phase 2 Withdrawn
Clinical Trials
13 trialsNCT05718297 2024-10-08
BOUNCE
ETOP IBCSG Partners Foundation
Phase 2 Withdrawn
NCT05757843 2024-09-19
Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab
Indiana University
Phase 2 Withdrawn
NCT04944173 2024-09-03
SCION
University of British Columbia
Phase 2 Withdrawn
NCT04625699 2023-06-06
Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment
Columbia University
Phase 2 Withdrawn
NCT05383001 2022-09-27
Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)
AIO-Studien-gGmbH
Phase 2 Withdrawn
NCT04470674 2022-03-03
Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients
Hoosier Cancer Research Network
Phase 2 Withdrawn
NCT04262869 2021-10-27
Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer
Emory University
Phase 2 Withdrawn
NCT04262375 2020-11-17
DOMINATION
University Health Network, Toronto
Phase 2 Withdrawn
NCT04262388 2020-11-17
DOME
University Health Network, Toronto
Phase 2 Withdrawn
NCT03419559 2019-04-16
Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer
Iovance Biotherapeutics, Inc.
Phase 2 Withdrawn
NCT03004105 2018-03-16
MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT02673814 2016-08-01
Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer
Peregrine Pharmaceuticals
Phase 2 Withdrawn